Drug Profile
Research programme: immuno-oncology therapeutics - Cue Biopharma
Alternative Names: CUE-100 series; IL-2 based CLU-100 series; RDI-STATLatest Information Update: 18 Apr 2023
Price :
$50
*
At a glance
- Originator Cue Biopharma
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin-2 replacements; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer